Approval · Notice of Compliance 32925 · 2024
MIRAPEX: Notice of Compliance 32925
Issued March 20, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32925
- Date
- March 20, 2024
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MIRAPEX | Not yet assigned | — |
Medicinal ingredients
- PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG per TAB
- PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.125 MG per TAB